PANCRASE

Pancrase is a Japanese organization primarily known for its pioneering role in mixed martial arts (MMA), but it has recently expanded into the healthcare and life sciences sectors through initiatives in regenerative medicine. Under the leadership of CEO Masakazu Sakai, the company has explored the application of sports-derived medical insights to broader therapeutic areas, including the use of CD34+ cell-based regenerative therapies. These efforts target conditions such as critical limb ischemia, non-union fractures, and diabetes, leveraging Japan's advanced regulatory environment for regenerative medicine. Pancrase collaborates with various healthcare and technology partners to integrate sports performance data with clinical research. The company aims to bridge the gap between elite athletic training and innovative medical treatments for the general population.